Science commentary stresses need for collaboration at local level in HIV-prevention studies

September 29, 2005

Clinical trials of drugs intended to prevent HIV infection in high-risk populations must be developed and carried out in close collaboration with the local communities and national governments of the countries in which they are conducted, according to 18 international leaders in HIV prevention writing in the current (Sept. 30, 2005) issue of Science.

Oral, daily use of the antiretroviral drug tenofovir is considered a key potential strategy for preventing infection of HIV. Clinical trials of the drug are in progress or proposed in numerous countries, including the U.S.

The co-authors advocate early involvement of community leaders and local investigators in the development of HIV-prophylaxis clinical trials, clear communication of research information, and the involvement of the local leaders and investigators in the development of local prevention and treatment infrastructures.

All too often, they note, studies in the last several years were marked by misinformation and miscommunication between these key constituencies.

The commentary outlines key issues involved, pointing out that, in those cases, questions about how the research should be carried out proved to be more controversial than the idea of the clinical trial itself.

"These recommended measures will help to build the type of local community trust that is the basis of successful research to find ways to stop the spread of HIV/AIDS," says lead author Robert Grant, MD, MPH, an associate investigator at the Gladstone Institute of Virology and Immunology and associate professor of medicine at the University of California, San Francisco (UCSF). "HIV pre-exposure chemoprophylaxis research is built on partnerships between sponsors, investigators, communities and governments."
-end-
The commentary is titled "Promote HIV Chemoprophylaxis Research, Don't Prevent It." The authors are affiliated with such institutions as the AIDS Research Consortium of Atlanta, the Peruvian-based Associacion Impacta Salud y Educacion and Red Peruana de Mujeres que Viven con VIH/Sida, Cornell University, New York, Family Health International, Research Triangle Park, North Carolina, the New York-based Gay Men's Health Crisis and the Treatment Action Group, the Ghana Health Service, the McGill University AIDS Center, Montreal, the San Francisco Department of Public Health, UCLA, UCSF, and the University of North Carolina, Chapel Hill.

UCSF is a leading university that consistently defines health care worldwide by conducting advanced biomedical research, educating graduate students in health care, and providing complex patient care.

The Gladstone Institute of Virology and Immunology is one of three research institutes of The J. David Gladstone Institutes, an independent, nonprofit biomedical research institution affiliated with UCSF. For further information, visit www.gladstone.ucsf.edu.

Gladstone Institutes

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.